Literature DB >> 15886814

Opposite effects of CX3CR1 receptor polymorphisms V249I and T280M on the development of acute coronary syndrome. A possible implication of fractalkine in inflammatory activation.

Alexander Niessner1, Rodrig Marculescu, Arvand Haschemi, Georg Endler, Gerlinde Zorn, Cornelia M Weyand, Gerald Maurer, Christine Mannhalter, Johann Wojta, Oswald Wagner, Kurt Huber.   

Abstract

Several lines of evidence suggest that the chemokine fractalkine (FKN) and its receptor CX3CR1 contribute to the accumulation of leukocytes in the atherosclerotic plaque. The M280 allele of the CX3CR1T280M polymorphism modulates leukocyte recruitment and is associated with lower prevalence of cardiovascular disease. The influence of V249I, another CX3CR1 polymorphism, is discussed controversially. We investigated the association of the alleles M280 and I249 of CX3CR1 with coronary artery disease (CAD) and with acute coronary syndrome (ACS). Additionally, we assessed their association with the soluble ligand FKN and inflammatory activation measured by high sensitivity C-reactive protein (hsCRP). The genotypes of the V249I and T280M polymorphisms were determined in 1152 patients with suspected CAD.720 (62.5%) individuals showed significant CAD with an ACS prevalence of 59.3%. Using multivariate regression, we found a harmful influence of I249 (adjusted OR=1.8, P<0.03) and a protective effect of M280 (adjusted OR=0.6, P<0.04) on the occurrence of ACS in patients with CAD. Correspondingly, patients with I249 but without M280 (17%) were at elevated risk of ACS (OR=1.6, P<0.04). During ACS these patients (carrying only I249) had significantly higher circulating concentrations of FKN and high sensitivity C-reactive protein (1.9- and 1.6-fold). We found no association of the I249 or the M280 allele with the occurrence of CAD. In conclusion, I249 and M280 have opposite effects on the occurrence of ACS. The presence of I249 not "balanced" by M280 confers an elevated risk of ACS. A FKN-mediated enhanced inflammatory activation might explain this increased risk.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15886814     DOI: 10.1160/TH04-11-0735

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  10 in total

1.  Polymorphism in chemokine receptor genes and risk of acute myocardial infarction in North Indian population.

Authors:  Neha Singh; Nakul Sinha; Sudeep Kumar; Chandra M Pandey; Suraksha Agrawal
Journal:  Mol Biol Rep       Date:  2011-07-10       Impact factor: 2.316

Review 2.  The fine balance of chemokines during disease: trafficking, inflammation, and homeostasis.

Authors:  Sandra M Cardona; Jenny A Garcia; Astrid E Cardona
Journal:  Methods Mol Biol       Date:  2013

Review 3.  Therapeutic targeting of chemokine interactions in atherosclerosis.

Authors:  Rory R Koenen; Christian Weber
Journal:  Nat Rev Drug Discov       Date:  2010-02       Impact factor: 84.694

Review 4.  Molecular genetics of atherosclerosis.

Authors:  Himadri Roy; Shalini Bhardwaj; Seppo Yla-Herttuala
Journal:  Hum Genet       Date:  2009-03-20       Impact factor: 4.132

5.  Touch of chemokines.

Authors:  Xavier Blanchet; Marcella Langer; Christian Weber; Rory R Koenen; Philipp von Hundelshausen
Journal:  Front Immunol       Date:  2012-07-12       Impact factor: 7.561

6.  Chorioamnionitis (ChA) modifies CX3CL1 (fractalkine) production by human amniotic epithelial cells (HAEC) under normoxic and hypoxic conditions.

Authors:  Dariusz Szukiewicz; Jan Kochanowski; Tarun Kumar Mittal; Michal Pyzlak; Grzegorz Szewczyk; Krzysztof Cendrowski
Journal:  J Inflamm (Lond)       Date:  2014-05-13       Impact factor: 4.981

7.  Two polymorphisms in the Fractalkine receptor CX3CR1 gene influence the development of atherosclerosis: a meta-analysis.

Authors:  Jian Wu; Rui-Xing Yin; Quan-Zhen Lin; Tao Guo; Guang-Yuan Shi; Jia-Qi Sun; Shao-Wen Shen; Qing Li
Journal:  Dis Markers       Date:  2014-08-26       Impact factor: 3.434

8.  CX3CR1 is a modifying gene of survival and progression in amyotrophic lateral sclerosis.

Authors:  Alan Lopez-Lopez; Josep Gamez; Emilio Syriani; Miguel Morales; Maria Salvado; Manuel J Rodríguez; Nicole Mahy; Jose M Vidal-Taboada
Journal:  PLoS One       Date:  2014-05-07       Impact factor: 3.240

Review 9.  The chemokine CX3CL1 (fractalkine) and its receptor CX3CR1: occurrence and potential role in osteoarthritis.

Authors:  Piotr Wojdasiewicz; Lukasz A Poniatowski; Andrzej Kotela; Jarosław Deszczyński; Ireneusz Kotela; Dariusz Szukiewicz
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2014-02-21       Impact factor: 4.291

Review 10.  Role of CX3CL1/CX3CR1 Signaling Axis Activity in Osteoporosis.

Authors:  Piotr Wojdasiewicz; Pawel Turczyn; Barbara Dobies-Krzesniak; Justyna Frasunska; Beata Tarnacka
Journal:  Mediators Inflamm       Date:  2019-11-12       Impact factor: 4.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.